Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Small Bowel Adenocarcinoma
Interventions
DRUG

Nanoliposomal irinotecan

Nanoliposomal Irinotecan 50 mg/m2 will be administered over 90 minutes (± 10 minutes) IV. All subjects must be pre-medicated prior to nanoliposomal irinotecan infusion with standard doses of dexamethasone and a 5-HT3 antagonist, or equivalent other anti-emetics (according to standard institutional practices).

DRUG

Oxaliplatin

Oxaliplatin 60 mg/m2 will be administered over 120 minutes (± 10 minutes) IV. Institutional standards may be used for all aspects of oxaliplatin administration including premedication administration.

DRUG

5 fluorouracil

5-FU will be administered as a continuous infusion over 46 hours. Subjects will go home with an infusion pump and return to clinic at the end of infusion for removal of the pump or, if possible, the pump may be removed at the subject's home (except on Cycle 1 Day 3).

DRUG

Leucovorin

Leucovorin 400 mg/m2 will be administered over 30 minutes IV.

Trial Locations (4)

23298

RECRUITING

Virginia Commonwealth University, Richmond

33612

RECRUITING

Moffitt Cancer Center, Tampa

60612

RECRUITING

University of Illinois Cancer Center, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ipsen

INDUSTRY

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

Tiago Biachi de Castria

OTHER